Header Logo

Connection

Lawrence Kushi to Chemotherapy, Adjuvant

Back to Details
This is a "connection" page, showing publications Lawrence Kushi has written about Chemotherapy, Adjuvant.
Lawrence Kushi
Connection Strength
1.554
Chemotherapy, Adjuvant
  1. Social Support and Treatment Delays in Breast Cancer Patients Within an Integrated Health Care System. Psychooncology. 2024 Nov; 33(11):e70025.
    View in: PubMed
    Score: 0.235
  2. Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system. Breast Cancer Res Treat. 2018 Aug; 170(3):623-631.
    View in: PubMed
    Score: 0.149
  3. Association Between Complementary and Alternative Medicine Use and Breast Cancer Chemotherapy Initiation: The Breast Cancer Quality of Care (BQUAL) Study. JAMA Oncol. 2016 Sep 01; 2(9):1170-6.
    View in: PubMed
    Score: 0.134
  4. Racial/Ethnic Disparities in Ovarian Cancer Treatment and Survival. Clin Cancer Res. 2016 Dec 01; 22(23):5909-5914.
    View in: PubMed
    Score: 0.133
  5. A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL). Breast Cancer Res Treat. 2016 07; 158(1):127-138.
    View in: PubMed
    Score: 0.131
  6. Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index. JAMA Oncol. 2015 Sep; 1(6):737-45.
    View in: PubMed
    Score: 0.125
  7. Noninitiation of adjuvant chemotherapy in women with localized breast cancer: the breast cancer quality of care study. J Clin Oncol. 2012 Nov 01; 30(31):3800-9.
    View in: PubMed
    Score: 0.102
  8. Associations of physical activity with quality of life and functional ability in breast cancer patients during active adjuvant treatment: the Pathways Study. Breast Cancer Res Treat. 2011 Sep; 129(2):521-9.
    View in: PubMed
    Score: 0.092
  9. Methodologic Approach to Defining Comorbidities in a Cohort of Patients With Cancer: An Example in the Optimal Breast Cancer Chemotherapy Dosing Study. JCO Clin Cancer Inform. 2025 Feb; 9:e2400231.
    View in: PubMed
    Score: 0.060
  10. Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019. Breast Cancer Res. 2024 Jun 13; 26(1):101.
    View in: PubMed
    Score: 0.057
  11. Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence. Breast Cancer Res Treat. 2020 Feb; 180(1):219-226.
    View in: PubMed
    Score: 0.042
  12. Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy. Breast Cancer Res Treat. 2018 Apr; 168(2):523-530.
    View in: PubMed
    Score: 0.036
  13. Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL). Breast Cancer Res Treat. 2016 05; 157(1):133-43.
    View in: PubMed
    Score: 0.033
  14. Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer. Breast Cancer. 2014 Nov; 21(6):780-5.
    View in: PubMed
    Score: 0.029
  15. Comparative effectiveness of adjunctive bevacizumab for advanced lung cancer: the cancer research network experience. J Thorac Oncol. 2014 May; 9(5):692-701.
    View in: PubMed
    Score: 0.028
  16. Interpersonal influences and attitudes about adjuvant therapy treatment decisions among non-metastatic breast cancer patients: an examination of differences by age and race/ethnicity in the BQUAL study. Breast Cancer Res Treat. 2013 Feb; 137(3):817-28.
    View in: PubMed
    Score: 0.026
  17. Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007. Breast Cancer Res Treat. 2013 Jan; 137(1):247-60.
    View in: PubMed
    Score: 0.026
  18. Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL). Breast Cancer Res Treat. 2012 Jul; 134(1):419-28.
    View in: PubMed
    Score: 0.025
  19. The Breast Cancer Quality of Care Study (BQUAL): a multi-center study to determine causes for noncompliance with breast cancer adjuvant therapy. Breast J. 2012 May-Jun; 18(3):203-13.
    View in: PubMed
    Score: 0.025
  20. Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2012 Jan; 131(2):607-17.
    View in: PubMed
    Score: 0.024
  21. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011 Apr; 126(2):529-37.
    View in: PubMed
    Score: 0.022
  22. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010 Sep 20; 28(27):4120-8.
    View in: PubMed
    Score: 0.022

© 2025 Kaiser Permanente